Ptc Therapeutics (PTCT) Payables: 2012-2025
Historic Payables for Ptc Therapeutics (PTCT) over the last 13 years, with Sep 2025 value amounting to $303.1 million.
- Ptc Therapeutics' Payables fell 9.87% to $303.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 9.58%. This contributed to the annual value of $304.3 million for FY2024, which is 22.37% down from last year.
- Per Ptc Therapeutics' latest filing, its Payables stood at $303.1 million for Q3 2025, which was down 10.56% from $338.9 million recorded in Q2 2025.
- In the past 5 years, Ptc Therapeutics' Payables ranged from a high of $392.0 million in Q4 2023 and a low of $205.6 million during Q1 2021.
- In the last 3 years, Ptc Therapeutics' Payables had a median value of $336.3 million in 2024 and averaged $338.5 million.
- As far as peak fluctuations go, Ptc Therapeutics' Payables soared by 43.53% in 2021, and later fell by 22.37% in 2024.
- Ptc Therapeutics' Payables (Quarterly) stood at $288.8 million in 2021, then increased by 10.94% to $320.4 million in 2022, then climbed by 22.35% to $392.0 million in 2023, then fell by 22.37% to $304.3 million in 2024, then fell by 9.87% to $303.1 million in 2025.
- Its Payables was $303.1 million in Q3 2025, compared to $338.9 million in Q2 2025 and $317.8 million in Q1 2025.